SCA
RIGL icon

SAC Capital Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

SAC Capital Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,734
Closed -$106K – 807
2014
Q1 		$106K Buy
2,734
+574
+27% +$20.5K ﹤0.01% 1667
2013
Q4 		$62K Buy
2,160
+840
+64% +$24.7K ﹤0.01% 1737
2013
Q3 		$47K Sell
1,320
-2,100
-61% -$76.6K ﹤0.01% 1724
2013
Q2 		$114K Buy
+3,420
New +$155K ﹤0.01% 1532

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SAC Capital Advisors's RIGL Position: Q2 2014 in Review

SAC Capital Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2014, closing a stake of 2,734 shares — an estimated $106K sold.

SAC Capital Advisors first reported a position in RIGL in Q2 2013 and held it in 4 quarters. The position peaked at $114K in Q2 2013. 103 funds tracked by Wall St. Rank hold RIGL as of Q2 2014.

  • SAC Capital Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,734 Rigel Pharmaceuticals shares in Q2 2014, an estimated $106K.
  • SAC Capital Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Rigel Pharmaceuticals position peaked at $114K in Q2 2013.
  • 103 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.